122 related articles for article (PubMed ID: 8831743)
1. [Report of nationwide questionnaire: intraperitoneal chemotherapy for advanced ovarian cancer based on clinical results--reports of 5th "Gynecologic Intraperitoneal Chemotherapy Study Group" meeting].
Umezawa S; Shimizu Y; Takizawa K; Nishimura H; Hatae M; Sasaki K; Yoshikawa H
Gan To Kagaku Ryoho; 1996 Sep; 23(10):1305-11. PubMed ID: 8831743
[TBL] [Abstract][Full Text] [Related]
2. Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer.
Almadrones L
Clin J Oncol Nurs; 2007 Apr; 11(2):211-6. PubMed ID: 17573270
[TBL] [Abstract][Full Text] [Related]
3. Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer.
Naumann RW; Sukumvanich P; Edwards RP
Gynecol Oncol; 2009 Jul; 114(1):37-41. PubMed ID: 19410281
[TBL] [Abstract][Full Text] [Related]
4. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer.
Lan C; Li Y; Liu J
Gynecol Oncol; 2009 Jul; 114(1):42-7. PubMed ID: 19398124
[TBL] [Abstract][Full Text] [Related]
6. Treatment of ovarian cancer with intraperitoneal chemotherapy.
Hydzik C
Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):15-20. PubMed ID: 19856603
[TBL] [Abstract][Full Text] [Related]
7. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
Petignat P; du Bois A; Bruchim I; Fink D; Provencher DM
Crit Rev Oncol Hematol; 2007 May; 62(2):137-47. PubMed ID: 17188887
[TBL] [Abstract][Full Text] [Related]
8. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
[TBL] [Abstract][Full Text] [Related]
10. Advanced cancer of the ovary: intraperitoneal chemotherapy as a new therapeutical option.
Fiorentini G; Filippeschi M; Turrisi G; Mambrini A; Giannessi PG; D'Alessandro M; Rossi S; Dentico P; Guadagni S; Cantore M; Madrigali A
In Vivo; 2009; 23(2):317-21. PubMed ID: 19414421
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?
Tummala MK; Alagarsamy S; McGuire WP
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1135-47. PubMed ID: 18588458
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
[TBL] [Abstract][Full Text] [Related]
13. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
Royer B; Delroeux D; Guardiola E; Combe M; Hoizey G; Montange D; Kantelip JP; Chauffert B; Heyd B; Pivot X
Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
[TBL] [Abstract][Full Text] [Related]
15. [Intraperitoneal chemotherapy in first-line combination treatment for advanced ovarian cancer].
Massard C; Lhommé C; Pautier P
Bull Cancer; 2007 Apr; 94(4):398-404. PubMed ID: 17449443
[TBL] [Abstract][Full Text] [Related]
16. Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer.
Zeimet AG; Reimer D; Radl AC; Reinthaller A; Schauer C; Petru E; Concin N; Braun S; Marth C
Anticancer Res; 2009 Jul; 29(7):2803-8. PubMed ID: 19596965
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
18. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
19. ACOG Committee Opinion No. 396. Intraperitoneal chemotherapy for ovarian cancer.
American College of Obstetricians and Gynecologists
Obstet Gynecol; 2008 Jan; 111(1):249. PubMed ID: 18165421
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.
Fung-Kee-Fung M; Provencher D; Rosen B; Hoskins P; Rambout L; Oliver T; Gotlieb W; Covens A;
Gynecol Oncol; 2007 Jun; 105(3):747-56. PubMed ID: 17368522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]